Tango Therapeutics Inc Cash Flow Conversion Efficiency
Tango Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Tango Therapeutics Inc (TNGX) has a cash flow conversion efficiency ratio of -0.038x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-38.87 Million) by net assets ($1.02 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Tango Therapeutics Inc (2019–2025)
Cash flow conversion efficiency of Tango Therapeutics Inc from 2019 to 2025. This chart illustrates how Tango Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View TNGX stock price and chart for real-time trading data and today's change.
Tango Therapeutics Inc Cash Flow Conversion Ratio Explained
Tango Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Tango Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tango Therapeutics Inc ranked by their cash flow conversion efficiency. Also see TNGX market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dorman Products Inc
NASDAQ:DORM
|
0.030x |
|
Andon Health Co Ltd
SHE:002432
|
0.024x |
|
FIELMANN AG (ADR/1/5)O.N.
F:FIE1
|
N/A |
|
Alm. Brand
CO:ALMB
|
-0.023x |
|
Predictive Discovery Ltd
AU:PDI
|
-0.030x |
|
Optics Technology Holding Co Ltd
SHE:300489
|
-0.004x |
|
Red Avenue New Materials Group Co Ltd
SHG:603650
|
0.048x |
|
MakeMyTrip Limited
NASDAQ:MMYT
|
-0.163x |
Annual Cash Flow Conversion Efficiency for Tango Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Tango Therapeutics Inc from 2019 to 2025. Review free cash flow generation of Tango Therapeutics Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $346.18 Million | $-138.89 Million | -0.401x | +39.13% |
| 2024-12-31 | $199.52 Million | $-131.50 Million | -0.659x | -41.40% |
| 2023-12-31 | $253.11 Million | $-117.98 Million | -0.466x | -6.61% |
| 2022-12-31 | $249.48 Million | $-109.08 Million | -0.437x | -153.22% |
| 2021-12-31 | $344.75 Million | $-59.53 Million | -0.173x | -109.51% |
| 2020-12-31 | $38.60 Million | $70.07 Million | 1.815x | +157.86% |
| 2019-12-31 | $7.91 Million | $-24.80 Million | -3.138x | -- |
About Tango Therapeutics Inc
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant … Read more